Leerink raised its Jazz Pharmaceuticals Plc (JAZZ) price target to $177 from $171, The Flyonthewall reports. The stock closed yesterday at $136.81 on volume of 1.1 million shares, roughly 300K higher from its 3 month average volume of 812,000 shares. The firm kept its ‘Outperform’ rating on the shares of the company.
Several analysts have recently commented on Jazz. Analysts at Buckingham Research and SunTrust Robinson Humphrey initiated coverage on Jazz in a report released on July 23, and July 16, respectively. The firms set a ‘Buy’ and a ‘Neutral’ rating on the stock with a $215.00 and $158.00 price target, respectively. Separately, analysts at Wells Fargo initiated coverage on Jazz Pharmaceuticals shares with an ‘Outperform’ rating in a research note on Wednesday, June 11. Finally, analysts at Cantor Fitzgerald maintained a ‘Hold’ rating on shares of Jazz in a research note issued to clients on Tuesday, May 27. They now have a $151.00 price target on the stock.
Shares of Jazz Pharmaceuticals fell 4% to $136.81 in regular trading Monday. Despite the decline, ticker is up 83.79% year-over-year, and 8.1% year-to-date.
JAZZ currently trades at a trailing-12 P/E of 104, a forward P/E of 13.52 and a P/E to growth ratio of 0.83. The median Wall Street price target on the company’s stock is $180 with a high target of $215.
Profitability-wise: Jazz Pharmaceuticals’ trailing-12 profit margin currently stand at nearly 8.70% while operating ones are at 40.50%. The $8.13 billion market cap company reported $251 million in cash vs. $1.2 billion in debt in its most recent quarter.
Jazz Pharmaceuticals is a biopharmaceuticals firm developing and commercializing pharma products for various medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.